Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN has been in the news recently: Regeneron Pharmaceuticals, in collaboration with Sanofi, announced results from two Phase 3 trials of itepekimab for patients with chronic obstructive pulmonary disease (COPD). This development highlights their ongoing commitment to advancing treatments in respiratory diseases.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
